GSK to make grant info public

Share this article:
GlaxoSmithKline will join Pfizer and Eli Lilly in reporting educational and charitable grants.

The company will provide quarterly reports on grants to hospitals, teaching institutions, managed care organizations, professional associations, patient advocacy groups and CME companies starting in February of next year.

"GSK sponsors a range of third-party independent educational programs to increase awareness and knowledge of health-related issues,” said GSK president, North American pharmaceuticals, Chris Viehbacher in a statement. “By publishing information about our grants, we transparently identify the support we offer for independent and quality education to improve the delivery of health care for patients.”

Lilly began reporting its grants publicly in May 2007, and Pfizer followed suit a year later. In March, AstraZeneca vowed to publish grant information biannually.

In April, responding to an inquiry by Sen. Charles Grassley (R-IA) demanding to know whether they would follow Lilly's lead, several companies, including Bristol-Myers Squibb, Medtronic and Boston Scientific, also agreed to begin making information on educational grants and payments to physicians public, while others, including Abbott, Amgen and Merck, told the senator they were working on it. Only one of the firms Grassley wrote – Schering-Plough – declined outright.  
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...